| 0.3925 -0.008 (-1.88%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.51 | 1-year : | 0.6 |
| Resists | First : | 0.43 | Second : | 0.51 |
| Pivot price | 0.38  |
|||
| Supports | First : | 0.35 |
Second : | 0.3 |
| MAs | MA(5) : | 0.37 |
MA(20) : | 0.36 |
| MA(100) : | 0.37 |
MA(250) : | 1.05 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 53 |
D(3) : | 46.3 |
| RSI | RSI(14): 56.5  |
|||
| 52-week | High : | 5.63 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GLMD ] has closed below upper band by 38.3%. Bollinger Bands are 11.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.4 - 0.4 | 0.4 - 0.4 |
| Low: | 0.35 - 0.36 | 0.36 - 0.36 |
| Close: | 0.39 - 0.39 | 0.39 - 0.4 |
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Thu, 18 Apr 2024
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results - PR Newswire
Thu, 04 Apr 2024
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 - PR Newswire
Mon, 20 Nov 2023
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study - PR Newswire
Fri, 22 Sep 2023
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PR Newswire
Fri, 14 Jul 2023
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering - PR Newswire
Thu, 01 Jun 2023
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 3.8 (%) |
| Held by Institutions | 9.4 (%) |
| Shares Short | 39 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -2.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -50.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|